Kedem Pharmaceuticals, Inc. has signed a contract with Corealis Pharma, Inc. for the production of Phase I clinical supplies of KDM-1102, the company’s second lead therapeutic drug. The KDM-1102 drug is a new sublingual formulation of propanolol. The formulation development is now completed and can be produced in large volume.

“We are pleased with the progress we have been making in our development program on KDM-1102, our second lead therapeutic drug for cardiovascular and anxiety attacks,” said Dr. Hassan Salari, president and chief executive officer of Kedem Pharmaceuticals.